Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 561Carcinoma, Non-Small-Cell Lung 481Ovarian Neoplasms 326Lung Neoplasms 203Fallopian Tube Neoplasms 152Neoplasms 150Triple Negative Breast Neoplasms 125Esophageal Neoplasms 125Stomach Neoplasms 121Neoplasm Metastasis 118Carcinoma, Ovarian Epithelial 114Endometrial Neoplasms 95Squamous Cell Carcinoma of Head and Neck 94Uterine Cervical Neoplasms 79Head and Neck Neoplasms 77Esophageal Squamous Cell Carcinoma 76Recurrence 48Adenocarcinoma of Lung 47Parkinson Disease 4, Autosomal Dominant Lewy Body 45Melanoma 42Carcinoma 42Urinary Bladder Neoplasms 41Adenocarcinoma Of Esophagus 36Small Cell Lung Carcinoma 34Carcinoma, Squamous Cell 34Prostatic Neoplasms 31Pancreatic Neoplasms 29Breast Neoplasms, Male 28Unspecified Adult Solid Tumor, Protocol Specific 27Colorectal Neoplasms 25

Interventions

pembrolizumab 2Docetaxel 2Cisplatin 2Bevacizumab 2130-nm albumin-bound paclitaxel 2taxane 1liposomal doxorubicin 1durvalumab 1cemiplimab 1atezolizumab 1Sorafenib 1Pemetrexed 1Paclitaxel 1Nivolumab 1Irinotecan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Drug Therapy 1Biosimilar Pharmaceuticals 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Vaccinia × Paclitaxel × Clear all
NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡